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trality and percentages determined. RESULTS: The data reveal a 100% written di-
agnosis for all prescriptions encountered. There were more females than males
(70% vs 30%). The average number of drugs per prescription was 6.0. About 61% of
the diabetic patients were also diagnosed with hypertension. Biguanides (95%)
were the commonest oral hypoglycaemic agent prescribed while calcium channel
antagonist (60%) was the commonest antihypertensive prescribed. The average
cost of medication per prescription was GHC 40.0 (Ghana cedi) – approx $20.5 (USD),
were as the average total cost of drugs per patient for the entire year was GHC 235.2
(Ghana cedi) – approx $120 (USD) CONCLUSIONS: The study demonstrates that
most patients attending the diabetic clinic in Ho Municipal Hospital are females.
The cost of diabetic medications to patient per prescription was expectedly high,
particularly due to the high number of drugs prescribed. Most diabetic patients
have hypertension. The prescription of ACE-I therefore need to be improved to
reduce the rate of cardiovascular complication in diabetes.
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OBJECTIVES: An update of health economics analysis of type 2 diabetes mellitus
(T2DM) in adult population in Turkey was performed. The relationship between the
presence of ophthalmic complications and cost components is reported in this
presentation. METHODS: Forty centres were selected from the list of centres in
which adult T2DM patients were followed on a routine basis. These centres were
representative of the country, since they were selected by two-stage cluster sam-
pling. Medical files were reviewed for two to five years prior to the study. Item
prices were obtained from the Ministry of Health and Social Security Organization
of Turkey. Costs are calculated simply as the total of all frequency-price products
(1€  2.321 Turkish Liras; Feb 2012). RESULTS: A total of 942 patients’ data were
included in the analysis. During the previous five years, 20.8% of the patients had at
least one visit or hospital stay related with ophthalmic complications (incl. diabetic
retinopathy, cataract, glaucoma). Total annual cost were 546.60€ and 382.13€ in
patients with and without ophthalmic complications, respectively. Costs related to
treatment, laboratory tests and health care services were 397.00€, 96.19€ and 53.41€
in patients with ophthalmic complications. These cost items, however, were quite
similar in patients without ophthalmic complications and in patients with isolated
ophthalmic complications, who has no systemic complication other than ophthal-
mic complication (for treatment 277.35€ vs. 297.07€, for laboratory tests 62.09€ vs.
85.82€, and for health care services 42.69€ vs. 40.27€). CONCLUSIONS: All compo-
nents of cost increased by 25% to 55% with the presence of ophthalmic complica-
tions. But the costs were almost similar in patients without ophthalmic complica-
tions and with isolated ophthalmic complications. Thus, the increase in cost seems
to be related with the presence of concomitant systemic complications other than
ophthalmic complications alone.
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OBJECTIVES: One of the main causes of premature death and disability in diabetic
patients are amputations of lower limbs which are the result of the development of
diabetic foot syndrome (DFS). Poland belongs to countries with a high rate of am-
putation. It is believed that the high rate of amputation is caused by significantly
higher costs of DFS treatment compared to cost of amputation. Indeed, in Poland
costs of DFS hospital treatment and amputation are almost equal. To answer the
question whether the costs of DFS hospital treatment are overestimated this study
estimated diabetic foot syndrome hospitalization costs based on data collected in
the one of leading DFS treatment centers.METHODS:Data on hospitalization costs
were estimated retrospectively, based on 2011 year disease documentation of all
DFS patients treated in the Department of Gastroenterology and Metabolic Dis-
eases of the Medical University of Warsaw. Values are presented in Euros (ex-
change rate: 1 EUR4.20 PLN). RESULTS: Data on 37 patients were analyzed. Total
cost of hospitalization per patient was estimated at the amount of 1765 EUR and
was almost 2-times higher than National Health Funds (NHF) reimbursement cost
of hospitalization. However, it should be noted that most of the costs were related
to bed costs (76%) which we believe are overestimated. The second cost position
was drug costs which accounted for only 11% of total costs. Other cost positions
such as: bandage, laboratory tests, diagnostic procedures and specialized team
help (i.e. anesthesia) amounted up to 4% of total cost. CONCLUSIONS: The reim-
bursement of diabetic foot syndrome treatment seems to be rather underestimated
than overestimated. However we suppose cost data provided by the hospital de-
partment for calculation are overestimated on bed costs and underestimated at
other positions especially on diagnostic procedures and bandage costs.
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OBJECTIVES: Subclinical hypothyroidism (SH) is typically defined as asymptom-
atic, characterized by slightly increased serum thyrotropin (TSH) levels and normal
serum free thyroxine concentrations. SH is common among general population,
especially in middle-aged women most often after menopause, and it is related to
cardiovascular events. The objective of this analysis was to estimate burden of
disease of SH and it’s evolution to clinical hypothyroidism (CH) in Spain.
METHODS: The recommended methodology by WHO for burden of disease studies
was used in this analysis. Disability-adjusted life years (DALY), years of life lost
(YLL), years life with disability (YLD) and mortality related to SH and CH were
calculated based on the adjusted attributable fraction. Prevalence of risk factors in
general population as well as HR, were obtained from literature review and official
sources (CMBD, hospital mortality register). RESULTS: In Spain, the number of
patients with SH and CH was estimated at 2,767,124. Among them, TSH concentra-
tions ranged between 4.5-6.9 mUI/L in 1,949,820 patients; between 6.9-10 mUI/L in
539,988 patients and between 10-19.9 mUI/L in 278,317 patients. Every year, 12,608
cardiovascular events, 1,388 cardiac deaths and 30,550 DALY (13,124 YLL and 17,426
YLD) would be attributable to SH. SH represented between 1.6-7.3% of cardiovas-
cular DALY. CONCLUSIONS: Both the extensive socioeconomic burden of SH and
the risk of developing clinical hypothyroidism and subsequent cardiovascular
health risks among patients with SH is to be considered. This suggests the utility of
SH screening for patients with risk factors, after assessing the efficiency of screen-
ing techniques.
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OBJECTIVES: In spite of the fact that primary care physicians are recommended to
following evidence-based clinical guidelines for management of diabetes, no stud-
ies have currently evaluated the clinical and economic impact of following diabetes
guidelines in Ontario. METHODS: To assess the short- and long-term impact of
treating patients with type II diabetes according to the guidelines in South-western
Ontario, two cohorts of newly diagnosed cases in 2002 were used. The first group
included patients who were not treated according to guidelines during the diag-
nostic year and the two years after diagnosis. The second group consisted with
individuals who were not treated according to the guidelines only during the first
year but for the two subsequent years of their diagnosis they were treated to
achieve the specified targets for HbA1c, blood pressure and lipid levels according to
guidelines. The short-term impacts of intervention in clinical outcomes were cal-
culated and were used to extrapolate to 40 years horizon using the Ontario Diabetes
Economic Model (ODEM). For each cohort, the event rates for seven diabetes-re-
lated complications, the mean difference in cost, and expected quality-adjusted
life-years (QALYs) were calculated based on baseline risk and 3-years following the
intervention. RESULTS: Almost 500 individuals newly diagnosed with diabetes in
2002 were not treated according to guidelines during the first year following diag-
nosis. Of those 236 were treated according to guidelines in the second and third
year following diagnosis and 259 individuals were not (the control cohort). A small
difference has been observed between the cohorts in terms of intermediate out-
comes as well as the lifetime predicted cumulative costs, QALYs, life expectancy
and event rate. CONCLUSIONS: The results of this study indicated that treating
patients to guidelines as used by physicians did not make an impact on the short
and long-term outcomes associated with diabetes.
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OBJECTIVES: Evidence from the A1chieve study (an international, prospective, ob-
servational study of insulin analogs within routine clinical practice) suggests the
glycemic control in type 2 diabetes patients in Saudi Arabia is poor. The aim of the
current analysis was to investigate the long-term clinical and economic benefits of
a 1% reduction in HbA1c in comparison with baseline levels for type 2 diabetes
patients in the Saudi Arabian setting. METHODS: Long-term projections were
made using the published and validated CORE Diabetes Model, over a 35-year time
horizon. Patient characteristics were taken from the Saudi Arabian cohort of the
A1chieve study. At baseline, mean (SD) patient age was 51(11) years, duration of
diabetes 10(6) years and HbA1c 9.8(0)%. Following a 1% HbA1c reduction in the
active arm, HbA1c was kept constant. Captured costs included concomitant med-
ications and diabetes-related complications. Costs of antihyperglycemic treatment
and adverse events were not included. Future costs and clinical outcomes were
discounted at a rate of 3% per annum. Costs are presented in 2011 Saudi Arabian
Riyals (SAR) and converted into Euros (EUR) (SAR 1 to EUR 0.2043). RESULTS: Im-
proved glycemic control was associated with improved life expectancy by 0.71
years (10.08 versus 9.37 years). Furthermore, reduction in HbA1c was associated
with increased time free from diabetes-related complications. Direct costs were
SAR 16,084 (EUR 3,286) lower in the reduced HbA1c group (SAR 173,514 [EUR 35,449]
versus SAR 189,598 [EUR 38,735]). This was driven by savings resulting from the
reduced incidence of complications. CONCLUSIONS: Baseline glycemic control in
A1chieve type 2 diabetes patients in Saudi Arabia is sub-optimal. Improvements in
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HbA1c are likely to lead to substantial clinical and economic benefits, driven by
reduced complication rates. The cost-effectiveness of interventions designed to
improve glycemic control in Saudi Arabia is worthy of investigation.
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OBJECTIVES:A1chieve is a prospective, international, observational study of basal,
bolus and biphasic insulin analogues in routine clinical practice. The present anal-
ysis aimed to evaluate the economic and clinical benefits associated with a 1%
reduction in HbA1c (relative to no change in HbA1c) in Malaysian A1chieve
patients. METHODS: Life expectancy, complication rate and the cost of complica-
tions were projected over a 35-year time horizon using the published CORE Diabe-
tes Model. At baseline, the mean (standard deviation) age of the cohort was 54 years
(11 years), duration of diabetes was 12 (8) years, HbA1c was 10% (1.8%) and body
mass index was 28.1 (5.1) kg/m2. HbA1c was reduced by 1%-point in the active
group versus the control group. Costs were reported in 2011 Malaysian Ringgits
(MYR) and converted to 2011 Euros (EUR) using the mid-market exchange rate on
June 30, 2011. Future costs and clinical outcomes were discounted annually at a
rate of 3.5%. RESULTS: A 1% reduction in HbA1c was associated with reduced costs
of treating diabetes complications and an increase in life expectancy. Undis-
counted life expectancy was improved by 0.36 years following HbA1c reduction
(7.53 versus 7.17 years). The time alive and free of any diabetes complications
increased from 0.31 years to 0.40 years in the HbA1creduction group. Over patient
lifetimes, improved HbA1c was associated with cost savings of EUR 682 [MYR 3,067]
(EUR 2,745 [MYR 13,607] versus EUR 3,427 [MYR 16,674]). The greatest cost savings
were associated with renal complications avoided. CONCLUSIONS: The A1chieve
study has shown that glycemic control is generally poor in routine clinical practice
in Malaysia. The present analysis showed that improved glycemic control would be
likely to bring substantial clinical and economic benefits to these patients, arising
primarily from reduced incidence of diabetes complications.
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OBJECTIVES: To estimate the long-term cost-effectiveness of adding twice-daily
exenatide (BID) to basal insulin in patients with type 2 diabetes from the perspec-
tive of NHS Scotland. Data from GWCO, a phase III, double-blind, randomized,
placebo-controlled trial, comparing the efficacy of adding exenatide BID to titrated
insulin glargine versus titrated insulin glargine alone, was used for the modelling
analysis. After 30 weeks, exenatide BID added to glargine was associated with
greater mean HbA1c reduction (-1.71% vs. -1.00%, p0.001) and weight reduction
(-1.78 kg vs. 0.96 kg, p0.001) compared to glargine alone. METHODS: A previ-
ously published and validated diabetes model (IMS CORE Diabetes Model) was used
to project 20-year clinical and cost outcomes based on the GWCO cohort (age 59
years, diabetes duration 12.3 years, HbA1c 8.41%) and efficacy and safety outcomes
from the GWCO trial. Costs were derived from published sources and expressed in
2011 Pounds Sterling (£). An annual discount rate of 3.5% was applied to future
costs and clinical benefits. RESULTS: In the base-case analysis exenatide BID plus
glargine was projected to improve quality-adjusted life expectancy by 0.183 qual-
ity-adjusted life years (QALYs) and life expectancy by 0.147 years compared to
glargine alone, at an additional cost of £1,721. The resulting cost per QALY was
£9,411. Increased pharmacy costs were partially offset by reduced costs associated
with diabetes complications with exenatide BID. Assuming a willingness-to-pay of
£20,000 per QALY gained, exenatide BID had a 99.8% probability of being cost-
effective. Sensitivity analyses showed that results were robust to variation in range
of model parameters. CONCLUSIONS: Based on results from GWCO clinical trial,
exenatide BID plus glargine is projected to be a cost-effective use of NHS Scotland
resources compared to glargine alone.
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OBJECTIVES: To assess cost-utility of switching type 2 diabetes patients to an in-
sulin detemir-based regimen after failure to achieve adequate control on 1) oral
antidiabetic agents (OADs) alone, or OAD in combination with 2) neutral protamine
Hagedorn (NPH) insulin, or 3) insulin glargine in Romania. METHODS: The CORE
Diabetes Model was used to model the long-term consequences. Efficacy results at
the beginning and at the end of the study as well as baseline demographics of the
patient cohort (subgroup analysis of the German cohort of PREDICTIVE study) were
used. The perspective was the health care services payer over life time (35-years).
The analysis used model default health state utility values. Cost data were derived
from DRG Data from the Center for Research and Evaluation of Healthcare Services
(Romania), CaNaMed National Catalogue of Medicines Prices (official tariff lists)
and expert opinion.RESULTS: In the 1st analysis (insulin detemirOADs vs. OADs)
QALYs increased by 0.399 years with insulin detemir. Total lifetime costs increased
by EUR 4,413 resulting in an incremental cost per QALY gained of EUR 11,050. In the
2nd analysis insulin detemir increased quality-adjusted life expectancy by 0.394
QALYs and total costs by EUR 2,340, with incremental cost per QALY gained of EUR
5,943. Transferring from insulin glargine  OADs to insulin detemir  OADs (3rd
analysis) increased QALYs by 0.319 years. Total costs increased by EUR 689 result-
ing in an incremental cost per QALY gained of EUR 2,160. CONCLUSIONS: Based on
efficacy data from an observational study and a validated health economics model,
insulin detemir was cost effective when compared to OAD alone, or insulin NPH 
OAD, or insulin glargine  OAD for the treatment of type 2 diabetes in the Roma-
nian health care setting.
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OBJECTIVES:Optimal glycemic control is a key goal in patients with type 2 diabetes
and is pivotal in reducing the risk of diabetes-related complications. The aim of the
present study was to investigate long-term clinical and economic benefits of a 1%
reduction in HbA1c versus baseline levels in patients enrolled in the A1chieve
study (an international, prospective, observational study of insulin use within rou-
tine clinical practice) in the Indonesian setting. METHODS: The analysis was per-
formed using the published and validated CORE Diabetes Model over a time hori-
zon of 35 years with future costs and clinical benefits were discounted at a rate of
3% per annum. At baseline patients had a mean HbA1c of 9.8%, the analysis com-
pared patients outcomes in which HbA1c remained at 9.8% in comparison with
reducing mean HbA1c by 1%; mean HbA1c was assumed to remain unchanged
throughout the simulation. Direct costs are presented in IDR (converted to EUR at a
rate of 1 EUR11,831 IDR). RESULTS: A 1% reduction in HbA1c from baseline led to
improvements in life expectancy and quality-adjusted life expectancy. Reducing
HbA1c from 9.8% to 8.8% improved life expectancy from 10.07 years to 10.69 years
(difference 0.61 years) and quality-adjusted life expectancy from 6.56 quality-ad-
justed life years (QALYs) to 7.04 QALYs (difference 0.48 QALYs). Mean direct costs
were also IDR 6,403,196 (EUR 541) lower in the reduced HbA1c group (IDR
242,721,221 [EUR 20,551] versus IDR 236,318,025 [EUR 20,026]), with the biggest
driver of cost savings being the reduced incidence of renal complications in the
reduced HbA1c group. CONCLUSIONS: Baseline glycemic control in patients with
diabetes in the Indonesian setting was sub-optimal; however, a 1% reduction in
HbA1c from baseline was associated with improved life expectancy and quality-
adjusted life expectancy as well as being cost-saving over a 35-year time horizon.
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INTRODUCTION: In T2DM, HbA1c tends to drift up over time and the extent to
which anti-hyperglycemic agents can maintain initial glucose lowering effect (or
durability) varies. HbA1c evolution is an important determinant of future outcomes
and costs. Currently there is no consensus on how to model upward drift in HbA1c
or the durability of treatments. OBJECTIVES: Review different approaches to mod-
eling HbA1c evolution and assess their impact on economic evaluations of T2DM
interventions. METHODS: We reviewed the ways in which HbA1c evolution has
been modeled. Lifetime simulations were performed that compared two hypothet-
ical treatments: 1) initial HbA1c reduction of 1.25% and annual cost of $1,000 and 2)
initial HbA1c reduction of 1% and annual cost of $200, using ECHO-T2DM, a vali-
dated micro-simulation model. . Treatment was intensified in both arms when
HbA1c exceeded 7.0%, first by adding basal insulin and subsequently by adding 3x
daily short-acting insulin. RESULTS: Four different approaches were identified: (1)
no HbA1c evolution; (2) constant increase in HbA1c, irrespective of treatment; (3)
constant treatment-specific increase in HbA1c; and (4) non-linear increase in
HbA1c, irrespective of treatment. The simulations confirmed that these assump-
tions are critical. While the incremental life-years (LY’s) and Quality-Adjusted LYs
(QALYs) were similar in the first 3 scenarios, the absolute values were highest for
(1). Cost-savings and QALY gains were largest in (3), which allowed HbA1c to drift
apart over time in each arm, and smallest in (2) (because treatment intensification
reduced the HbA1c gap). The incremental cost-effectiveness ratio (ICER) ranged
from $3,196 in (3) to $32,444 in (2). (4) could not be implemented in this version of
ECHO-T2DM. CONCLUSIONS: Assumptions used to model HbA1c evolution have
important consequences for estimates of cost-effectiveness, a 10-fold difference in
the ICER in this hypothetical example, and should be addressed with sensitivity
analysis in health economic evaluations.
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OBJECTIVES: To investigate the economic benefits of a 1% reduction in HbA1c in
comparison with baseline levels in patients with type 2 diabetes in Algeria enrolled
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